TrialBreast cancer research and treatment2023

Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.

Priya Rastogi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.